Abivax SA, a clinical-stage biotechnology company, announced the closing of its underwritten public offering of 11,679,400 American Depositary Shares (ADSs) in the United States, raising approximately $747.5 million in gross proceeds. The offering, which includes the full exercise of the underwriters' option to purchase additional ADSs, aims to finance the company's operations into the fourth quarter of 2027. This financial strategy supports Abivax's ambition to achieve a 12-month cash runway following its planned NDA submission for Ulcerative Colitis. The company's Ordinary Shares are listed on Euronext Paris under the symbol "ABVX," and its ADSs are on the Nasdaq Global Market. The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital, BTIG, and Van Lanschot Kempen as co-managers. An automatic shelf registration statement on Form F-3, including a prospectus, was filed with the SEC and is available on their website.